David B Buller1, Dallas R English1, Mary Klein Buller1, Jody Simmons1, James A Chamberlain1, Melanie Wakefield1, Suzanne Dobbinson1. 1. David B. Buller and Mary Klein Buller are with Klein Buendel, Inc., Golden, CO. Dallas R. English is with the Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Jody Simmons, Melanie Wakefield, and Suzanne Dobbinson are with the Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne. James A. Chamberlain is with the Cancer Epidemiology Centre, Cancer Council Victoria.
Abstract
OBJECTIVES: To test whether shade sails will increase the use of passive recreation areas (PRAs). METHODS: We conducted a stratified randomized pretest-posttest controlled design study in Melbourne, Australia, and Denver, Colorado, in 2010 to 2014. We randomized a sample of 144 public parks with 2 PRAs in full sun in a 1:3 ratio to treatment or control. Shade sails were built at 1 PRA per treatment park. The outcome was any use of the study PRA (n = 576 pretest and n = 576 posttest observations; 100% follow-up). RESULTS: Compared with control PRAs (adjusted probability of use: pretest = 0.14, posttest = 0.17), use of treatment PRAs (pretest = 0.10, posttest = 0.32) was higher at posttest (odds ratio [OR] = 3.91; 95% confidence interval [CI] = 1.71, 8.94). Shade increased use of PRAs in Denver (control: pretest = 0.18, posttest = 0.19; treatment: pretest = 0.16, posttest = 0.47) more than Melbourne (control: pretest = 0.11, posttest = 0.14; shaded: pretest = 0.06, posttest = 0.19; OR = 2.98; 95% CI = 1.09, 8.14). CONCLUSIONS: Public investment in shade is warranted for skin cancer prevention and may be especially useful in the United States. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02971709.
RCT Entities:
OBJECTIVES: To test whether shade sails will increase the use of passive recreation areas (PRAs). METHODS: We conducted a stratified randomized pretest-posttest controlled design study in Melbourne, Australia, and Denver, Colorado, in 2010 to 2014. We randomized a sample of 144 public parks with 2 PRAs in full sun in a 1:3 ratio to treatment or control. Shade sails were built at 1 PRA per treatment park. The outcome was any use of the study PRA (n = 576 pretest and n = 576 posttest observations; 100% follow-up). RESULTS: Compared with control PRAs (adjusted probability of use: pretest = 0.14, posttest = 0.17), use of treatment PRAs (pretest = 0.10, posttest = 0.32) was higher at posttest (odds ratio [OR] = 3.91; 95% confidence interval [CI] = 1.71, 8.94). Shade increased use of PRAs in Denver (control: pretest = 0.18, posttest = 0.19; treatment: pretest = 0.16, posttest = 0.47) more than Melbourne (control: pretest = 0.11, posttest = 0.14; shaded: pretest = 0.06, posttest = 0.19; OR = 2.98; 95% CI = 1.09, 8.14). CONCLUSIONS: Public investment in shade is warranted for skin cancer prevention and may be especially useful in the United States. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02971709.
Authors: Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Billie Giles-Corti; Anne Vernez-Moudon; Rodrigo Reis; Gavin Turrell; Andrew L Dannenberg; Hannah Badland; Sarah Foster; Melanie Lowe; James F Sallis; Mark Stevenson; Neville Owen Journal: Lancet Date: 2016-09-23 Impact factor: 79.321
Authors: Mona Saraiya; Karen Glanz; Peter A Briss; Phyllis Nichols; Cornelia White; Debjani Das; S Jay Smith; Bernice Tannor; Angela B Hutchinson; Katherine M Wilson; Nisha Gandhi; Nancy C Lee; Barbara Rimer; Ralph C Coates; Jon F Kerner; Robert A Hiatt; Patricia Buffler; Phyllis Rochester Journal: Am J Prev Med Date: 2004-12 Impact factor: 5.043
Authors: David B Buller; Suzanne Dobbinson; Dallas R English; Melanie Wakefield; Mary Klein Buller Journal: Contemp Clin Trials Date: 2017-02-07 Impact factor: 2.226
Authors: Suzanne J Dobbinson; Jody Simmons; James A Chamberlain; Robert J MacInnis; Jo Salmon; Petra K Staiger; Melanie Wakefield; Jenny Veitch Journal: Int J Environ Res Public Health Date: 2020-08-21 Impact factor: 3.390
Authors: Suzanne Jane Dobbinson; David Bard Buller; James Andrew Chamberlain; Jody Simmons; Mary Klein Buller Journal: Int J Environ Res Public Health Date: 2022-08-25 Impact factor: 4.614
Authors: Pazit Levinger; Jeremy Dunn; Maya Panisset; Briony Dow; Frances Batchelor; Stuart J H Biddle; Gustavo Duque; Keith D Hill Journal: BMC Public Health Date: 2021-06-22 Impact factor: 3.295